ClinicalTrials.gg
CompletedNCT02477670Updated May 13, 2026Results posted

Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Residual Schizophrenia

A Phase 2 interventional study of AVP-786 and Placebo in Schizophrenia, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 17 sites in United States. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-05-13.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
145
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 120 studies in Schizophrenia by Otsuka Holdings Co., Ltd. — 3 open to participants now, 4 under way, 3 of them phase 3. Schizophrenia · Otsuka Holdings Co., Ltd..

Enrollment
53rd of 111
145 · median 125
Started
2015
with 2 others
Phase 2
9 of 120
none open now
Registered
71st of 120
by date

Among the 120 studies in Schizophrenia by Otsuka Holdings Co., Ltd., this one is the 53rd largest by enrollment of the 111 interventional ones that give a count, is one of 3 that started in 2015, is one of 9 in phase 2, and was the 71st registered.

Schizophrenia

3,574 studies on the registry are indexed under Schizophrenia; 496 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

3 of the 120 studies in Schizophrenia by Otsuka Holdings Co., Ltd. are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 334 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 259 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 120 studies in Schizophrenia by Otsuka Holdings Co., Ltd., or all of them as a file.
02

Study summary

The objectives of this 12-week study are to evaluate the efficacy, safety, and tolerability of AVP-786 as an adjunctive treatment compared with placebo in patients with residual schizophrenia.

03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • Negative Symptoms
  • Schizophrenia
  • AVP-786
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who meet diagnostic criteria for schizophrenia using the M.I.N.I. version 6.0.
  • Patients must meet PANSS criteria
  • Patients currently receiving atypical antipsychotics are eligible provided they are on a stable dose

Exclusion criteria

Exclusion Criteria:

  • Patients with current major depressive disorder (MDD)
  • Patients with extrapyramidal syndrome secondary to their ongoing antipsychotic medication
  • Patients currently using anticholinergic medications
  • Recent in-patient hospitalization
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
145 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo capsules administered twice a day over a 12-week period

    Drug: Placebo

  • Experimental
    AVP-786

    AVP-786 dose 2 capsules administered twice a day over a 12-week period

    Drug: AVP-786

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the 16-Item Negative Symptom Assessment (NSA-16) Total Score at Week 6 and Week 12

    The NSA-16 is a measure of the presence, severity, and range of negative symptoms associated with schizophrenia. It has a high interrater and test-retest reliability across languages and cultures. The NSA-16 uses a 5-factor model to describe negative symptoms: (1) communication, (2) emotion/affect, (3) social involvement, (4) motivation, and (5) retardation. The possible NSA-16 total score ranges from 16 to 96, with a higher score indicating a worse condition. Change was Baseline was calculated as the post-Baseline value minus the Baseline value.

    Time frame: Baseline and Week 6 (Stage 1); Baseline (Week 6) and Week 12 (Stage 2)

Secondary outcomes

  1. Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 6 and Week 12

    The PANSS is a 30-item clinical scale that is extensively used as a reliable and valid measure for negative symptom trials. The PANNS consists of 6 subscales: positive subscale; negative subscale; general psychopathology subscale; prosocial factors (active social avoidance, emotional withdrawal, passive/apathetic social withdrawal, stereotyped thinking, hallucinatory behavior, suspiciousness/persecution); Marder negative factors (blunted affect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, lack of spontaneity and flow of conversation, motor retardation, active social avoidance); excitement component (excitement, hostility, tension, uncooperativeness, poor impulse control). Each item was scored from "1" (absent) to "7" (extremely severe). The PANSS total score ranges from 30 to 210, with a higher score indicating greater severity of symptoms. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

    Time frame: Baseline and Week 6 (Stage 1); Baseline (Week 6) and Week 12 (Stage 2)

  2. Change From Baseline in the PANSS Negative Subscale Score at Week 6 and Week 12

    The negative subscale includes items N1 - N7 in the PANSS. Each item was scored from "1" (absent) to "7" (extremely severe). The score ranges from 7 to 49, with higher scores indicative of greater severity of the negative symptoms. Change from Baseline was calculated as the post-Baseline score minus the Baseline score.

    Time frame: Baseline and Week 6 (Stage 1); Baseline (Week 6) and Week 12 (Stage 2)

  3. Change From Baseline in the PANSS Marder Negative Factor Score at Week 6 and Week 12

    The Marder negative factors comprise 7 items of the PANSS: N1 (blunted affect); N2 (emotional withdrawal); N3 (poor rapport); N4 (passive/apathetic social withdrawal); N6 (lack of spontaneity and flow of conversation); G7 (motor retardation), and G16 (active social avoidance). Each item is scored from "1" (absent) to "7" (extremely severe). The score ranges from 7 to 49, with higher scores indicative of greater severity of the negative symptoms of schizophrenia. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

    Time frame: Baseline and Week 6 (Stage 1); Baseline (Week 6) and Week 12 (Stage 2)

  4. Change From Baseline in the PANSS Prosocial Factor Subscale Score at Week 6 at Week 12

    The prosocial factors include items: G16 (active social avoidance); N2 (emotional withdrawal); N4 (passive/apathetic social withdrawal); N7 (stereotyped thinking); P3 (hallucinatory behavior); and P6 (suspiciousness/persecution) in the PANSS. Each item was scored from "1" (absent) to "7" (extremely severe). The score ranges from 6 to 42, with higher scores indicative of greater severity of the specific negative symptoms. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

    Time frame: Baseline and Week 6 (Stage 1); Baseline (Week 6) and Week 12 (Stage 2)

  5. Change From Baseline in the PANSS Positive Subscale Score at Week 6 and Week 12

    The positive subscale includes items P1 - P7 in the PANSS. Each item is scored from "1" (absent) to "7" (extremely severe). The score ranges from 7 to 49, with higher scores indicative of greater severity of the positive symptoms of schizophrenia. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

    Time frame: Baseline and Week 6 (Stage 1); Baseline (Week 6) and Week 12 (Stage 2)

  6. Change From Baseline in the PANSS General Psychopathology Subscale Score at Week 6 and Week 12

    The general psychopathology subscale includes items G1 - G16 in the PANSS. Each item was scored from "1" (absent) to "7" (extremely severe). The score ranges from 16 to 112, with higher scores indicative of greater severity of symptoms of schizophrenia. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

    Time frame: Baseline and Week 6 (Stage 1); Baseline (Week 6) and Week 12 (Stage 2)

  7. Change From Baseline in the PANSS Excitement Component Subscale Score at Week 6 and Week 12

    The excitement component includes items: P4 (excitement); P7 (hostility); G4 (tension); G8 (uncooperativeness); and G14 (poor impulse control). Each item is scored from "1" (absent) to "7" (extremely severe). The score ranges from 5 to 35, with higher scores indicative of greater severity of symptoms. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

    Time frame: Baseline and Week 6 (Stage 1); Baseline (Week 6) and Week 12 (Stage 2)

  8. Change From Baseline in the NSA-16 Communication Domain Score at Week 6 and Week 12

    NSA-16 Communication Factor Domain scores range from 4 to 24, with higher scores indicating greater clinical severity of symptoms. Negative values indicate improvement. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

    Time frame: Baseline and Week 6 (Stage 1); Baseline (Week 6) and Week 12 (Stage 2)

  9. Change From Baseline in the NSA-16 Emotion/Affect Domain Score at Week 6 and Week 12

    NSA-16 Emotion/Affect Domain scores range from 3 to 18, with higher scores indicating a greater clinical severity of symptoms. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

    Time frame: Baseline and Week 6 (Stage 1); Baseline (Week 6) and Week 12 (Stage 2)

  10. Change From Baseline in the NSA-16 Social Involvement Domain Score at Week 6 and Week 12

    NSA-16 Social Involvement Factor Domain scores range from 3 to 18, with higher scores indicating greater clinical severity of symptoms. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

    Time frame: Baseline and Week 6 (Stage 1); Baseline (Week 6) and Week 12 (Stage 2)

  11. Change From Baseline in the NSA-16 Motivation Domain Score at Week 6 and Week 12

    NSA-16 Motivation Factor Domain scores range from 4 to 24, with higher scores indicating greater clinical severity of symptoms. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

    Time frame: Baseline and Week 6 (Stage 1); Baseline (Week 6) and Week 12 (Stage 2)

  12. Change From Baseline in the NSA-16 Retardation Domain Score at Week 6 at Week 12

    NSA-16 Retardation Factor Domain scores range from 3 to 18, with higher scores indicating greater clinical severity of symptoms. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

    Time frame: Baseline and Week 6 (Stage 1); Baseline (Week 6) and Week 12 (Stage 2)

  13. Change From Baseline in the NSA-16 Global Negative Symptoms Score at Week 6 and Week 12

    The global negative symptoms rating in the NSA-16 is a single score based on the overall impression of severity of negative symptoms on a 1 to 7 scale, where higher scores indicate greater severity. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

    Time frame: Baseline and Week 6 (Stage 1); Baseline (Week 6) and Week 12 (Stage 2)

  14. Change From Baseline in the NSA-16 Global Level of Functioning Score at Week 6 and Week 12

    The global level of functioning is a single score on a scale of 1 to 7 that provides the overall assessment of the participant's level of functioning, with higher scores indicative of severe impairment in functioning. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

    Time frame: Baseline and Week 6 (Stage 1); Baseline (Week 6) and Week 12 (Stage 2)

  15. Change From Baseline in the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB) Composite Score at Week 6 and Week 12

    The MCCB is the standard tool for assessing cognitive change in trials of cognitive-enhancing agents in schizophrenia and is used to provide a relatively brief evaluation of key cognitive domains relevant to schizophrenia and related disorders. It is made up of 10 tests that measure 7 cognitive domains: Speed of Processing; Attention/Vigilance; Working Memory; Verbal Learning; Visual Learning; Reasoning and Problem Solving; and Social Cognition. The MCCB was to be conducted at approximately the same time of day (+/- 2 hours) and preferably in the morning. The MCCB composite score ranges from 0 to 70, with higher scores indicative of less severe cognition symptoms. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

    Time frame: Baseline and Week 6 (Stage 1); Baseline (Week 6) and Week 12 (Stage 2)

  16. Mean Actual Clinical Global Impression of Severity (CGI-S) of Illness Score at Week 6 and Week 12

    The CGI is an assessment of a participant's global functioning prior to and after initiating study medication and provides an overall clinician-determined summary measure that takes into account knowledge of the participant's history, psychosocial circumstances, symptoms, behavior, and the impact of the symptoms on the participant's ability to function. It is based on a 7-point scale that requires the clinician to rate the severity of the participant's illness at the time of assessment, relative to the clinician's past experience with participants who have the same diagnosis. Considering the total clinical experience, a participant is assessed on severity of mental illness at the time of rating: 1 (normal, not at all ill); 2 (borderline mentally ill); 3 (mildly ill); 4 (moderately ill); 5 (markedly ill); 6 (severely ill); or 7 (among the most extremely ill participants). Scores range from 1 to 7, with higher scores indicative of greater severity of illness.

    Time frame: Week 6 (Stage 1); Week 12 (Stage 2)

  17. Mean Actual Clinical Global Impression of Change (CGI-C) Score at Week 6 and Week 12

    The CGI is an assessment of the participant's global functioning prior to and after initiating a study medication and provides an overall clinician-determined summary measure that takes into account all available information, including knowledge of the participant's history, psychosocial circumstances, symptoms, behavior, and the impact of the symptoms on the participant's ability to function. It is based on a 7-point scale that requires the clinician to rate the change of the participant's condition at the time of assessment, relative to the clinician's past experience with the participant's condition at admission. Considering the total clinical experienced, a participant is assessed for change of mental illness as: 1 (very much improved); 2 (much improved); 3 (minimally improved); 4 (no change); 5 (minimally worse); 6 (much worse); or 7 (very much worse). Scores range from 1 to 7, with higher scores indicative of greater severity of illness.

    Time frame: Baseline, Week 6 (Stage 1), Week 12 (Stage 2)

  18. Mean Actual Patient Global Impression of Change (PGI-C) Score at Week 6 at Week 12

    The PGI-C is a 7-point, participant-rated scale used to assess treatment response as: 0=Not assessed; 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally 6=worse; or 7=very much worse. Week 6 and Week 12 scores are relative to Stage 1 Baseline.

    Time frame: Baseline, Week 6 (Stage 1), Week 12 (Stage 2)

  19. Change From Baseline in the Calgary Depression Scale for Schizophrenia (CDSS) Total Score at Week 6 and Week 12

    The CDSS is a 9-item scale derived from the Hamilton Depression Scale (Ham-D) that is designed to assess depression specifically in participants with schizophrenia. Unlike the Ham-D, the CDSS does not contain depressive symptoms that overlap with negative symptoms of schizophrenia, such as anhedonia and social withdrawal. Each item on the scale is scored as: 0 (absent); 1 (mild); 2 (moderate); or 3 (severe). The CDSS is obtained by adding each of the item scores. A score above 6 has an 82% specificity and 85% sensitivity for predicting the presence of a major depressive episode. The CDSS score ranges from 0 to 27, with higher scores indicative of severe symptoms of depression. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

    Time frame: Baseline and Week 6 (Stage 1); Baseline (Week 6) and Week 12 (Stage 2)

  20. Change From Baseline in the Effort Expenditure for Reward Task (EEfRT) Score for Baseline Press Rate at Week 6 and Week 12

    The EEfRT is a multi-trial computerized task in which participants are given the opportunity on each trial to choose between 2 tasks that differ in difficulty level and are associated with varying levels of monetary reward. The test measures drug effects on the willingness to expend effort in relation to the amount of reward or probability of reward. The ratio of hard task choices with moderate probability reward is used as an outcome measure for negative symptoms. EEfRT scores are analyzed for 8 variables. Variable 1 is the Baseline press rate and is defined as the value coded as average presses/second. Scores range from 0 to 9, with higher scores indicative of faster button pressing ability. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

    Time frame: Baseline and Week 6 (Stage 1); Baseline (Week 6) and Week 12 (Stage 2)

  21. Change From Baseline in the EEfRT Score for Choice Reaction Time (RT) 1st 50 at Week 6 and Week 12

    The EEfRT is a multi-trial computerized test that reliably measures drug effects on the willingness to expend effort in relation to the amount of reward or probability of reward. For each trial, participants are asked to choose between 2 tasks that differ in difficulty level and are associated with varying levels of monetary reward. EEfRT scores are analyzed for 8 variables. Variable 2 is the choice RT and is defined as the average RT measured in milliseconds for making a choice during the first 50 trials. Scores range from 0 to 10,000. The target range is greater than 500. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

    Time frame: Baseline and Week 6 (Stage 1); Baseline (Week 6) and Week 12 (Stage 2)

  22. Change From Baseline in the EEfRT Score for Completed Tasks at Week 6 and Week 12

    The EEfRT is a multi-trial computerized test that reliably measures drug effects on the willingness to expend effort in relation to the amount of reward or probability of reward. For each trial, participants are asked to choose between 2 tasks that differ in difficulty level and are associated with varying levels of monetary reward. EEfRT scores are analyzed for 8 variables. Variable 3 is the proportion of completed task (easy or hard) during the first 50 trials. Scores range from 0 to 1, with higher scores indicative of better task compliance. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

    Time frame: Baseline and Week 6 (Stage 1); Baseline (Week 6) and Week 12 (Stage 2)

  23. Change From Baseline in the EEfRT Score for 12% Probability-Proportion High Effort Opts at Week 6 and Week 12

    The EEfRT is a multi-trial computerized test that reliably measures drug effects on the willingness to expend effort in relation to the amount of reward or probability of reward. For each trial, participants are asked to choose between 2 tasks that differ in difficulty level and are associated with varying levels of monetary reward. EEfRT scores are analyzed for 8 variables. Variable 4 is the proportion of hard task choices made for the low (12%) probability condition during the first 50 trials of the task. Scores range from 0 to 1, with higher scores indicative of greater effort expenditure. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

    Time frame: Baseline and Week 6 (Stage 1); Baseline (Week 6) and Week 12 (Stage 2)

  24. Change From Baseline in the EEfRT Score for 50% Probability-Proportion High Effort Opts 1st 50 at Week 6 and Week 12

    The EEfRT is a multi-trial computerized test that reliably measures drug effects on the willingness to expend effort in relation to the amount of reward or probability of reward. For each trial, participants are asked to choose between 2 tasks that differ in difficulty level and are associated with varying levels of monetary reward. EEfRT scores are analyzed for 8 variables. Variable 5 is the proportion of hard task choices made for the medium (50%) probability condition during the first 50 trials of the task. Scores range from 0 to 1, with higher scores indicative of greater effort expenditure. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

    Time frame: Baseline and Week 6 (Stage 1); Baseline (Week 6) and Week 12 (Stage 2)

  25. Change From Baseline in the EEfRT Score for 88% Probability-Proportion High Effort Opts 1st 50 at Week 6 and Week 12

    The EEfRT is a multi-trial computerized test that reliably measures drug effects on the willingness to expend effort in relation to the amount of reward or probability of reward. For each trial, participants are asked to choose between 2 tasks that differ in difficulty level and are associated with varying levels of monetary reward. EEfRT scores are analyzed for 8 variables. Variable 6 is the proportion of hard task choices made for the hard (88%) probability condition during the first 50 trials of the task. Scores range from 0 to 1, with higher scores indicative of greater effort expenditure. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

    Time frame: Baseline and Week 6 (Stage 1); Baseline (Week 6) and Week 12 (Stage 2)

  26. Change From Baseline in the EEfRT Score for All-Proportion High Effort Opts 1st 50 at Week 6 and Week 12

    The EEfRT is a multi-trial computerized test that reliably measures drug effects on the willingness to expend effort in relation to the amount of reward or probability of reward. For each trial, participants are asked to choose between 2 tasks that differ in difficulty level and are associated with varying levels of monetary reward. EEfRT scores are analyzed for 8 variables. Variable 7 is the overall proportion of hard task choices made for the first 50 trials of the task. Scores range from 0 to 1, with higher scores indicative of greater effort expenditure. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

    Time frame: Baseline and Week 6 (Stage 1); Baseline (Week 6) and Week 12 (Stage 2)

  27. Change From Baseline in the EEfRT Score for Difference - Proportion High Effort Opts 1st 50 at Week 6 and Week 12

    The EEfRT is a multi-trial computerized test that reliably measures drug effects on the willingness to expend effort in relation to the amount of reward or probability of reward. For each trial, participants are asked to choose between 2 tasks that differ in difficulty level and are associated with varying levels of monetary reward. EEfRT scores are analyzed for 8 variables. Variable 8 is the difference between the proportion of hard task choices made for the high probability condition during the first 50 trials of the task. Scores range from -1 to 1, with higher scores indicative of greater sensitivity to probability information. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

    Time frame: Baseline and Week 6 (Stage 1); Baseline (Week 6) and Week 12 (Stage 2)

  28. Number of Participants With a Reduction of 20% or Greater in the PANSS Total Score at Week 6 and Week 12

    Treatment effect was evaluated by analyzing the proportion of participants with a 20% reduction from Baseline in the PANSS total score with SPCD analysis.

    Time frame: Baseline and Week 6 (Stage 1); Baseline (Week 6) and Week 12 (Stage 2)

  29. Change From Baseline in the 4-Item NSA (NSA-4) Total Score at Week 6 and Week 12

    The NSA-4 is comprised of the 4 NSA-16 items as follows: 1) restricted speech quantity, 2) emotion: reduced range, 3) reduced social drive, and 4) reduced interests, as well as an overall global rating of negative symptoms. The NSA-16 is a measure of the presence, severity, and range of negative symptoms associated with schizophrenia. It has a high interrater and test-retest reliability across languages and cultures. The possible NSA-4 total score ranges from 4 to 24, with higher scores indicating greater clinical severity of symptoms. Change was Baseline was calculated as the post-Baseline value minus the Baseline value.

    Time frame: Baseline and Week 6 (Stage 1); Baseline (Week 6) and Week 12 (Stage 2)

07

Results

Posted Sep 16, 2020

Participant flow

Of the 145 participants randomized at the beginning of the study, 127 patients met the criteria for the Modified Intent-to-Treat (mITT) Population and were included in the Stage 1 mITT Population. A total of 108 participants were included in the Stage 2 mITT Population.

Stage 1
Participant flow — Stage 1
MilestoneStage 1: AVP-786Stage 1: PlaceboStage 1 Placebo Non-responders; Stage 2: PlaceboStage 1 Placebo Non-responders; Stage 2: AVP-786Stage 1 Placebo Responders; Stage 2: PlaceboStage 1 Placebo Responders; Stage 2: AVP-786Stage 1 AVP-786; Stage 2: AVP-786
Started478000000
Completed436700000
Not completed41300000
Withdrew: Adverse event2700000
Withdrew: Lost to follow-up0200000
Withdrew: Withdrawal by subject1200000
Withdrew: Non-compliance with study drug1200000
Stage 2
Participant flow — Stage 2
MilestoneStage 1: AVP-786Stage 1: PlaceboStage 1 Placebo Non-responders; Stage 2: PlaceboStage 1 Placebo Non-responders; Stage 2: AVP-786Stage 1 Placebo Responders; Stage 2: PlaceboStage 1 Placebo Responders; Stage 2: AVP-786Stage 1 AVP-786; Stage 2: AVP-786
Started0030332142
Completed0028322142
Not completed0021000
Withdrew: Adverse event0010000
Withdrew: Antipsychotic medication changed0010000
Withdrew: Withdrawal by subject0001000

Outcome measures

PrimaryChange From Baseline in the 16-Item Negative Symptom Assessment (NSA-16) Total Score at Week 6 and Week 12

The NSA-16 is a measure of the presence, severity, and range of negative symptoms associated with schizophrenia. It has a high interrater and test-retest reliability across languages and cultures. The NSA-16 uses a 5-factor model to describe negative symptoms: (1) communication, (2) emotion/affect, (3) social involvement, (4) motivation, and (5) retardation. The possible NSA-16 total score ranges from 16 to 96, with a higher score indicating a worse condition. Change was Baseline was calculated as the post-Baseline value minus the Baseline value.

Time frame:
Baseline and Week 6 (Stage 1); Baseline (Week 6) and Week 12 (Stage 2)
Reported as:
Mean · score on a scale
Change From Baseline in the 16-Item Negative Symptom Assessment (NSA-16) Total Score at Week 6 and Week 12
score on a scaleStage 1: AVP-786Stage 1: PlaceboStage 1 Placebo Non-responders; Stage 2: PlaceboStage 1 Placebo Non-responders; Stage 2: AVP-786Stage 1 Placebo Responders; Stage 2: PlaceboStage 1 Placebo Responders; Stage 2: AVP-786Stage 1 AVP-786; Stage 2: AVP-786
Stage 1 Baseline61.0 ± 7.5360.4 ± 7.71—————
Change from Baseline at Week 6-5.0 ± 5.64-3.4 ± 5.54—————
Stage 2 Baseline——57.6 ± 9.3957.6 ± 9.09———
Change from Baseline at Week 12——-2.4 ± 5.88-3.7 ± 6.41———
Statistical analysis
  • Stage 1: AVP-786 vs Stage 1: Placebo vs Stage 1 Placebo Non-responders; Stage 2: Placebo vs Stage 1 Placebo Non-responders; Stage 2: AVP-786 · Mixed Models Analysis · p = 0.073 · Spcd weighted ols z-statistic: -1.79 · 95% CI -3.75 to 0.17
SecondaryChange From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 6 and Week 12

The PANSS is a 30-item clinical scale that is extensively used as a reliable and valid measure for negative symptom trials. The PANNS consists of 6 subscales: positive subscale; negative subscale; general psychopathology subscale; prosocial factors (active social avoidance, emotional withdrawal, passive/apathetic social withdrawal, stereotyped thinking, hallucinatory behavior, suspiciousness/persecution); Marder negative factors (blunted affect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, lack of spontaneity and flow of conversation, motor retardation, active social avoidance); excitement component (excitement, hostility, tension, uncooperativeness, poor impulse control). Each item was scored from "1" (absent) to "7" (extremely severe). The PANSS total score ranges from 30 to 210, with a higher score indicating greater severity of symptoms. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

Time frame:
Baseline and Week 6 (Stage 1); Baseline (Week 6) and Week 12 (Stage 2)
Reported as:
Mean · score on a scale
Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 6 and Week 12
score on a scaleStage 1: AVP-786Stage 1: PlaceboStage 1 Placebo Non-responders; Stage 2: PlaceboStage 1 Placebo Non-responders; Stage 2: AVP-786Stage 1 Placebo Responders; Stage 2: PlaceboStage 1 Placebo Responders; Stage 2: AVP-786Stage 1 AVP-786; Stage 2: AVP-786
Stage 1 Baseline67.4 ± 8.2668.7 ± 7.99—————
Change from Baseline at Week 6-4.7 ± 6.98-2.5 ± 6.50—————
Stage 2 Baseline——67.1 ± 9.0065.6 ± 8.07———
Change from Baseline at Week 12——-1.4 ± 7.64-4.0 ± 7.71———
Statistical analysis
  • Stage 1: AVP-786 vs Stage 1: Placebo vs Stage 1 Placebo Non-responders; Stage 2: Placebo vs Stage 1 Placebo Non-responders; Stage 2: AVP-786 · Mixed Models Analysis · p = 0.025 · Spcd weighted ols z-statistic: -2.25 · 95% CI -4.21 to -0.29
SecondaryChange From Baseline in the PANSS Negative Subscale Score at Week 6 and Week 12

The negative subscale includes items N1 - N7 in the PANSS. Each item was scored from "1" (absent) to "7" (extremely severe). The score ranges from 7 to 49, with higher scores indicative of greater severity of the negative symptoms. Change from Baseline was calculated as the post-Baseline score minus the Baseline score.

Time frame:
Baseline and Week 6 (Stage 1); Baseline (Week 6) and Week 12 (Stage 2)
Reported as:
Mean · score on a scale
Change From Baseline in the PANSS Negative Subscale Score at Week 6 and Week 12
score on a scaleStage 1: AVP-786Stage 1: PlaceboStage 1 Placebo Non-responders; Stage 2: PlaceboStage 1 Placebo Non-responders; Stage 2: AVP-786Stage 1 Placebo Responders; Stage 2: PlaceboStage 1 Placebo Responders; Stage 2: AVP-786Stage 1 AVP-786; Stage 2: AVP-786
Stage 1 Baseline24.6 ± 3.5125.2 ± 3.64—————
Change from Baseline at Week 6-2.2 ± 3.33-1.5 ± 3.81—————
Stage 2 Baseline——24.4 ± 4.5523.6 ± 4.53———
Change from Baseline at Week 12——-1.0 ± 2.69-2.3 ± 3.12———
Statistical analysis
  • Stage 1: AVP-786 vs Stage 1: Placebo vs Stage 1 Placebo Non-responders; Stage 2: Placebo vs Stage 1 Placebo Non-responders; Stage 2: AVP-786 · Mixed Models Analysis · p = 0.027 · Spcd weighted ols z-statistic: -2.20 · 95% CI -4.16 to -0.24
SecondaryChange From Baseline in the PANSS Marder Negative Factor Score at Week 6 and Week 12

The Marder negative factors comprise 7 items of the PANSS: N1 (blunted affect); N2 (emotional withdrawal); N3 (poor rapport); N4 (passive/apathetic social withdrawal); N6 (lack of spontaneity and flow of conversation); G7 (motor retardation), and G16 (active social avoidance). Each item is scored from "1" (absent) to "7" (extremely severe). The score ranges from 7 to 49, with higher scores indicative of greater severity of the negative symptoms of schizophrenia. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

Time frame:
Baseline and Week 6 (Stage 1); Baseline (Week 6) and Week 12 (Stage 2)
Reported as:
Mean · score on a scale
Change From Baseline in the PANSS Marder Negative Factor Score at Week 6 and Week 12
score on a scaleStage 1: AVP-786Stage 1: PlaceboStage 1 Placebo Non-responders; Stage 2: PlaceboStage 1 Placebo Non-responders; Stage 2: AVP-786Stage 1 Placebo Responders; Stage 2: PlaceboStage 1 Placebo Responders; Stage 2: AVP-786Stage 1 AVP-786; Stage 2: AVP-786
Stage 1 Baseline24.1 ± 4.2424.2 ± 3.81—————
Change from Baseline at Week 6-2.1 ± 3.34-1.6 ± 3.48—————
Stage 2 Baseline——23.0 ± 4.6222.3 ± 5.45———
Change from Baseline at Week 12——-0.8 ± 2.80-2.5 ± 4.27———
Statistical analysis
  • Stage 1: AVP-786 vs Stage 1: Placebo vs Stage 1 Placebo Non-responders; Stage 2: Placebo vs Stage 1 Placebo Non-responders; Stage 2: AVP-786 · Mixed Models Analysis · p = 0.024 · Spcd weighted ols z-statistic: -2.26 · 95% CI -4.22 to -0.3
SecondaryChange From Baseline in the PANSS Prosocial Factor Subscale Score at Week 6 at Week 12

The prosocial factors include items: G16 (active social avoidance); N2 (emotional withdrawal); N4 (passive/apathetic social withdrawal); N7 (stereotyped thinking); P3 (hallucinatory behavior); and P6 (suspiciousness/persecution) in the PANSS. Each item was scored from "1" (absent) to "7" (extremely severe). The score ranges from 6 to 42, with higher scores indicative of greater severity of the specific negative symptoms. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

Time frame:
Baseline and Week 6 (Stage 1); Baseline (Week 6) and Week 12 (Stage 2)
Reported as:
Mean · score on a scale
Change From Baseline in the PANSS Prosocial Factor Subscale Score at Week 6 at Week 12
score on a scaleStage 1: AVP-786Stage 1: PlaceboStage 1 Placebo Non-responders; Stage 2: PlaceboStage 1 Placebo Non-responders; Stage 2: AVP-786Stage 1 Placebo Responders; Stage 2: PlaceboStage 1 Placebo Responders; Stage 2: AVP-786Stage 1 AVP-786; Stage 2: AVP-786
Stage 1 Baseline18.3 ± 3.2418.4 ± 2.92—————
Change from Baseline at Week 6-2.0 ± 2.18-1.1 ± 2.53—————
Stage 2 Baseline——17.7 ± 3.2717.0 ± 3.30———
Change from Baseline at Week 12——-0.7 ± 2.02-1.4 ± 2.35———
Statistical analysis
  • Stage 1: AVP-786 vs Stage 1: Placebo vs Stage 1 Placebo Non-responders; Stage 2: Placebo vs Stage 1 Placebo Non-responders; Stage 2: AVP-786 · Mixed Models Analysis · p = 0.009 · Spcd weighted ols z-statistic: -2.60 · 95% CI -4.56 to -0.64
SecondaryChange From Baseline in the PANSS Positive Subscale Score at Week 6 and Week 12

The positive subscale includes items P1 - P7 in the PANSS. Each item is scored from "1" (absent) to "7" (extremely severe). The score ranges from 7 to 49, with higher scores indicative of greater severity of the positive symptoms of schizophrenia. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

Time frame:
Baseline and Week 6 (Stage 1); Baseline (Week 6) and Week 12 (Stage 2)
Reported as:
Mean · score on a scale
Change From Baseline in the PANSS Positive Subscale Score at Week 6 and Week 12
score on a scaleStage 1: AVP-786Stage 1: PlaceboStage 1 Placebo Non-responders; Stage 2: PlaceboStage 1 Placebo Non-responders; Stage 2: AVP-786Stage 1 Placebo Responders; Stage 2: PlaceboStage 1 Placebo Responders; Stage 2: AVP-786Stage 1 AVP-786; Stage 2: AVP-786
Stage 1 Baseline13.6 ± 3.6513.4 ± 2.81—————
Change from Baseline at Week 6-0.8 ± 2.63-0.3 ± 2.57—————
Stage 2 Baseline——13.1 ± 3.6413.3 ± 3.39———
Change from Baseline at Week 12——-0.4 ± 1.99-0.3 ± 2.47———
Statistical analysis
  • Stage 1: AVP-786 vs Stage 1: Placebo vs Stage 1 Placebo Non-responders; Stage 2: Placebo vs Stage 1 Placebo Non-responders; Stage 2: AVP-786 · Mixed Models Analysis · p = 0.700 · Spcd weighted ols z-statistic: -0.39 · 95% CI -2.35 to 1.57
SecondaryChange From Baseline in the PANSS General Psychopathology Subscale Score at Week 6 and Week 12

The general psychopathology subscale includes items G1 - G16 in the PANSS. Each item was scored from "1" (absent) to "7" (extremely severe). The score ranges from 16 to 112, with higher scores indicative of greater severity of symptoms of schizophrenia. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

Time frame:
Baseline and Week 6 (Stage 1); Baseline (Week 6) and Week 12 (Stage 2)
Reported as:
Mean · score on a scale
Change From Baseline in the PANSS General Psychopathology Subscale Score at Week 6 and Week 12
score on a scaleStage 1: AVP-786Stage 1: PlaceboStage 1 Placebo Non-responders; Stage 2: PlaceboStage 1 Placebo Non-responders; Stage 2: AVP-786Stage 1 Placebo Responders; Stage 2: PlaceboStage 1 Placebo Responders; Stage 2: AVP-786Stage 1 AVP-786; Stage 2: AVP-786
Stage 1 Baseline29.1 ± 4.6630.1 ± 5.05—————
Change from Baseline at Week 6-1.7 ± 4.04-0.7 ± 3.21—————
Stage 2 Baseline——29.7 ± 5.4028.7 ± 4.84———
Change from Baseline at Week 12——0.0 ± 5.14-1.3 ± 5.10———
Statistical analysis
  • Stage 1: AVP-786 vs Stage 1: Placebo vs Stage 1 Placebo Non-responders; Stage 2: Placebo vs Stage 1 Placebo Non-responders; Stage 2: AVP-786 · Mixed Models Analysis · p = 0.054 · Spcd weighted ols z-statistic: -1.93 · 95% CI -3.89 to 0.03
SecondaryChange From Baseline in the PANSS Excitement Component Subscale Score at Week 6 and Week 12

The excitement component includes items: P4 (excitement); P7 (hostility); G4 (tension); G8 (uncooperativeness); and G14 (poor impulse control). Each item is scored from "1" (absent) to "7" (extremely severe). The score ranges from 5 to 35, with higher scores indicative of greater severity of symptoms. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

Time frame:
Baseline and Week 6 (Stage 1); Baseline (Week 6) and Week 12 (Stage 2)
Reported as:
Mean · score on a scale
Change From Baseline in the PANSS Excitement Component Subscale Score at Week 6 and Week 12
score on a scaleStage 1: AVP-786Stage 1: PlaceboStage 1 Placebo Non-responders; Stage 2: PlaceboStage 1 Placebo Non-responders; Stage 2: AVP-786Stage 1 Placebo Responders; Stage 2: PlaceboStage 1 Placebo Responders; Stage 2: AVP-786Stage 1 AVP-786; Stage 2: AVP-786
Stage 1 Baseline6.2 ± 1.576.3 ± 2.10—————
Change from Baseline at Week 6-0.4 ± 1.64-0.2 ± 1.57—————
Stage 2 Baseline——5.8 ± 1.276.7 ± 2.59———
Change from Baseline at Week 12——0.0 ± 2.04-0.1 ± 1.77———
Statistical analysis
  • Stage 1: AVP-786 vs Stage 1: Placebo vs Stage 1 Placebo Non-responders; Stage 2: Placebo vs Stage 1 Placebo Non-responders; Stage 2: AVP-786 · Mixed Models Analysis · p = 0.723 · Spcd weighted ols z-statistic: -0.35 · 95% CI -2.31 to 1.61
SecondaryChange From Baseline in the NSA-16 Communication Domain Score at Week 6 and Week 12

NSA-16 Communication Factor Domain scores range from 4 to 24, with higher scores indicating greater clinical severity of symptoms. Negative values indicate improvement. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

Time frame:
Baseline and Week 6 (Stage 1); Baseline (Week 6) and Week 12 (Stage 2)
Reported as:
Mean · score on a scale
Change From Baseline in the NSA-16 Communication Domain Score at Week 6 and Week 12
score on a scaleStage 1: AVP-786Stage 1: PlaceboStage 1 Placebo Non-responders; Stage 2: PlaceboStage 1 Placebo Non-responders; Stage 2: AVP-786Stage 1 Placebo Responders; Stage 2: PlaceboStage 1 Placebo Responders; Stage 2: AVP-786Stage 1 AVP-786; Stage 2: AVP-786
Stage 1 Baseline12.5 ± 2.5412.6 ± 2.71—————
Change from Baseline at Week 6-1.3 ± 2.32-1.0 ± 1.91—————
Stage 2 Baseline——12.0 ± 2.9811.8 ± 3.12———
Change from Baseline at Week 12——-0.4 ± 1.86-1.0 ± 1.56———
Statistical analysis
  • Stage 1: AVP-786 vs Stage 1: Placebo vs Stage 1 Placebo Non-responders; Stage 2: Placebo vs Stage 1 Placebo Non-responders; Stage 2: AVP-786 · Mixed Models Analysis · p = 0.064 · Spcd weighted ols z-statistic: -1.85 · 95% CI -3.81 to 0.11
SecondaryChange From Baseline in the NSA-16 Emotion/Affect Domain Score at Week 6 and Week 12

NSA-16 Emotion/Affect Domain scores range from 3 to 18, with higher scores indicating a greater clinical severity of symptoms. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

Time frame:
Baseline and Week 6 (Stage 1); Baseline (Week 6) and Week 12 (Stage 2)
Reported as:
Mean · score on a scale
Change From Baseline in the NSA-16 Emotion/Affect Domain Score at Week 6 and Week 12
score on a scaleStage 1: AVP-786Stage 1: PlaceboStage 1 Placebo Non-responders; Stage 2: PlaceboStage 1 Placebo Non-responders; Stage 2: AVP-786Stage 1 Placebo Responders; Stage 2: PlaceboStage 1 Placebo Responders; Stage 2: AVP-786Stage 1 AVP-786; Stage 2: AVP-786
Stage 1 Baseline12.6 ± 2.1112.2 ± 1.81—————
Change from Baseline at Week 6-1.0 ± 1.28-0.6 ± 1.54—————
Stage 2 Baseline——11.7 ± 1.8411.7 ± 2.09———
Change from Baseline at Week 12——-0.4 ± 1.50-0.6 ± 1.36———
Statistical analysis
  • Stage 1: AVP-786 vs Stage 1: Placebo vs Stage 1 Placebo Non-responders; Stage 2: Placebo vs Stage 1 Placebo Non-responders; Stage 2: AVP-786 · Mixed Models Analysis · p = 0.100 · Spcd weighted ols z-statistic: -1.64 · 95% CI -3.6 to 0.32
SecondaryChange From Baseline in the NSA-16 Social Involvement Domain Score at Week 6 and Week 12

NSA-16 Social Involvement Factor Domain scores range from 3 to 18, with higher scores indicating greater clinical severity of symptoms. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

Time frame:
Baseline and Week 6 (Stage 1); Baseline (Week 6) and Week 12 (Stage 2)
Reported as:
Mean · score on a scale
Change From Baseline in the NSA-16 Social Involvement Domain Score at Week 6 and Week 12
score on a scaleStage 1: AVP-786Stage 1: PlaceboStage 1 Placebo Non-responders; Stage 2: PlaceboStage 1 Placebo Non-responders; Stage 2: AVP-786Stage 1 Placebo Responders; Stage 2: PlaceboStage 1 Placebo Responders; Stage 2: AVP-786Stage 1 AVP-786; Stage 2: AVP-786
Stage 1 Baseline12.2 ± 2.0212.2 ± 2.20—————
Change from Baseline at Week 6-0.6 ± 1.87-0.3 ± 1.92—————
Stage 2 Baseline——12.1 ± 2.1212.0 ± 2.56———
Change from Baseline at Week 12——-0.8 ± 1.40-1.1 ± 2.51———
Statistical analysis
  • Stage 1: AVP-786 vs Stage 1: Placebo vs Stage 1 Placebo Non-responders; Stage 2: Placebo vs Stage 1 Placebo Non-responders; Stage 2: AVP-786 · Mixed Models Analysis · p = 0.388 · Spcd weighted ols z-statistic: -0.86 · 95% CI -2.82 to 1.1
SecondaryChange From Baseline in the NSA-16 Motivation Domain Score at Week 6 and Week 12

NSA-16 Motivation Factor Domain scores range from 4 to 24, with higher scores indicating greater clinical severity of symptoms. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

Time frame:
Baseline and Week 6 (Stage 1); Baseline (Week 6) and Week 12 (Stage 2)
Reported as:
Mean · score on a scale
Change From Baseline in the NSA-16 Motivation Domain Score at Week 6 and Week 12
score on a scaleStage 1: AVP-786Stage 1: PlaceboStage 1 Placebo Non-responders; Stage 2: PlaceboStage 1 Placebo Non-responders; Stage 2: AVP-786Stage 1 Placebo Responders; Stage 2: PlaceboStage 1 Placebo Responders; Stage 2: AVP-786Stage 1 AVP-786; Stage 2: AVP-786
Stage 1 Baseline16.5 ± 2.3716.7 ± 2.33—————
Change from Baseline at Week 6-1.4 ± 1.96-0.9 ± 1.80—————
Stage 2 Baseline——15.8 ± 2.6115.8 ± 2.39———
Change from Baseline at Week 12——-0.4 ± 2.13-0.4 ± 2.09———
Statistical analysis
  • Stage 1: AVP-786 vs Stage 1: Placebo vs Stage 1 Placebo Non-responders; Stage 2: Placebo vs Stage 1 Placebo Non-responders; Stage 2: AVP-786 · Mixed Models Analysis · p = 0.367 · Spcd weighted ols z-statistic: -0.90 · 95% CI -2.86 to 1.06
SecondaryChange From Baseline in the NSA-16 Retardation Domain Score at Week 6 at Week 12

NSA-16 Retardation Factor Domain scores range from 3 to 18, with higher scores indicating greater clinical severity of symptoms. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

Time frame:
Baseline and Week 6 (Stage 1); Baseline (Week 6) and Week 12 (Stage 2)
Reported as:
Mean · score on a scale
Change From Baseline in the NSA-16 Retardation Domain Score at Week 6 at Week 12
score on a scaleStage 1: AVP-786Stage 1: PlaceboStage 1 Placebo Non-responders; Stage 2: PlaceboStage 1 Placebo Non-responders; Stage 2: AVP-786Stage 1 Placebo Responders; Stage 2: PlaceboStage 1 Placebo Responders; Stage 2: AVP-786Stage 1 AVP-786; Stage 2: AVP-786
Stage 1 Baseline7.2 ± 1.546.7 ± 1.61—————
Change from Baseline at Week 6-0.8 ± 1.46-0.6 ± 1.20—————
Stage 2 Baseline——6.0 ± 2.006.3 ± 2.05———
Change from Baseline at Week 12——-0.3 ± 1.20-0.5 ± 1.81———
Statistical analysis
  • Stage 1: AVP-786 vs Stage 1: Placebo vs Stage 1 Placebo Non-responders; Stage 2: Placebo vs Stage 1 Placebo Non-responders; Stage 2: AVP-786 · Mixed Models Analysis · p = 0.447 · Spcd weighted ols z-statistic: -0.76 · 95% CI -2.72 to 1.2
SecondaryChange From Baseline in the NSA-16 Global Negative Symptoms Score at Week 6 and Week 12

The global negative symptoms rating in the NSA-16 is a single score based on the overall impression of severity of negative symptoms on a 1 to 7 scale, where higher scores indicate greater severity. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

Time frame:
Baseline and Week 6 (Stage 1); Baseline (Week 6) and Week 12 (Stage 2)
Reported as:
Mean · score on a scale
Change From Baseline in the NSA-16 Global Negative Symptoms Score at Week 6 and Week 12
score on a scaleStage 1: AVP-786Stage 1: PlaceboStage 1 Placebo Non-responders; Stage 2: PlaceboStage 1 Placebo Non-responders; Stage 2: AVP-786Stage 1 Placebo Responders; Stage 2: PlaceboStage 1 Placebo Responders; Stage 2: AVP-786Stage 1 AVP-786; Stage 2: AVP-786
Stage 1 Baseline4.6 ± 0.644.6 ± 0.61—————
Change from Baseline at Week 6-0.4 ± 0.68-0.2 ± 0.64—————
Stage 2 Baseline——4.3 ± 0.714.4 ± 0.75———
Change from Baseline at Week 12——-0.1 ± 0.51-0.5 ± 0.75———
Statistical analysis
  • Stage 1: AVP-786 vs Stage 1: Placebo vs Stage 1 Placebo Non-responders; Stage 2: Placebo vs Stage 1 Placebo Non-responders; Stage 2: AVP-786 · Mixed Models Analysis · p = 0.026 · Spcd weighted ols z-statistic: -2.23 · 95% CI -4.19 to -0.27
SecondaryChange From Baseline in the NSA-16 Global Level of Functioning Score at Week 6 and Week 12

The global level of functioning is a single score on a scale of 1 to 7 that provides the overall assessment of the participant's level of functioning, with higher scores indicative of severe impairment in functioning. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

Time frame:
Baseline and Week 6 (Stage 1); Baseline (Week 6) and Week 12 (Stage 2)
Reported as:
Mean · score on a scale
Change From Baseline in the NSA-16 Global Level of Functioning Score at Week 6 and Week 12
score on a scaleStage 1: AVP-786Stage 1: PlaceboStage 1 Placebo Non-responders; Stage 2: PlaceboStage 1 Placebo Non-responders; Stage 2: AVP-786Stage 1 Placebo Responders; Stage 2: PlaceboStage 1 Placebo Responders; Stage 2: AVP-786Stage 1 AVP-786; Stage 2: AVP-786
Stage 1 Baseline4.7 ± 0.734.6 ± 0.63—————
Change from Baseline at Week 6-0.4 ± 0.61-0.2 ± 0.55—————
Stage 2 Baseline——4.5 ± 0.744.4 ± 0.70———
Change from Baseline at Week 12——-0.3 ± 0.52-0.3 ± 0.64———
Statistical analysis
  • Stage 1: AVP-786 vs Stage 1: Placebo vs Stage 1 Placebo Non-responders; Stage 2: Placebo vs Stage 1 Placebo Non-responders; Stage 2: AVP-786 · Mixed Models Analysis · p = 0.106 · Spcd weighted ols z-statistic: -1.62 · 95% CI -3.58 to 0.34
SecondaryChange From Baseline in the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB) Composite Score at Week 6 and Week 12

The MCCB is the standard tool for assessing cognitive change in trials of cognitive-enhancing agents in schizophrenia and is used to provide a relatively brief evaluation of key cognitive domains relevant to schizophrenia and related disorders. It is made up of 10 tests that measure 7 cognitive domains: Speed of Processing; Attention/Vigilance; Working Memory; Verbal Learning; Visual Learning; Reasoning and Problem Solving; and Social Cognition. The MCCB was to be conducted at approximately the same time of day (+/- 2 hours) and preferably in the morning. The MCCB composite score ranges from 0 to 70, with higher scores indicative of less severe cognition symptoms. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

Time frame:
Baseline and Week 6 (Stage 1); Baseline (Week 6) and Week 12 (Stage 2)
Reported as:
Mean · score on a scale
Change From Baseline in the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB) Composite Score at Week 6 and Week 12
score on a scaleStage 1: AVP-786Stage 1: PlaceboStage 1 Placebo Non-responders; Stage 2: PlaceboStage 1 Placebo Non-responders; Stage 2: AVP-786Stage 1 Placebo Responders; Stage 2: PlaceboStage 1 Placebo Responders; Stage 2: AVP-786Stage 1 AVP-786; Stage 2: AVP-786
Stage 1 Baseline32.5 ± 11.3728.8 ± 13.09—————
Change from Baseline at Week 61.2 ± 5.111.6 ± 4.55—————
Stage 2 Baseline——31.7 ± 14.9928.9 ± 10.69———
Change from Baseline at Week 12——-1.6 ± 4.061.6 ± 3.71———
Statistical analysis
  • Stage 1: AVP-786 vs Stage 1: Placebo vs Stage 1 Placebo Non-responders; Stage 2: Placebo vs Stage 1 Placebo Non-responders; Stage 2: AVP-786 · Mixed Models Analysis · p = 0.074 · Spcd weighted ols z-statistic: 1.78 · 95% CI -0.18 to 3.74
SecondaryMean Actual Clinical Global Impression of Severity (CGI-S) of Illness Score at Week 6 and Week 12

The CGI is an assessment of a participant's global functioning prior to and after initiating study medication and provides an overall clinician-determined summary measure that takes into account knowledge of the participant's history, psychosocial circumstances, symptoms, behavior, and the impact of the symptoms on the participant's ability to function. It is based on a 7-point scale that requires the clinician to rate the severity of the participant's illness at the time of assessment, relative to the clinician's past experience with participants who have the same diagnosis. Considering the total clinical experience, a participant is assessed on severity of mental illness at the time of rating: 1 (normal, not at all ill); 2 (borderline mentally ill); 3 (mildly ill); 4 (moderately ill); 5 (markedly ill); 6 (severely ill); or 7 (among the most extremely ill participants). Scores range from 1 to 7, with higher scores indicative of greater severity of illness.

Time frame:
Week 6 (Stage 1); Week 12 (Stage 2)
Reported as:
Mean · score on a scale
Mean Actual Clinical Global Impression of Severity (CGI-S) of Illness Score at Week 6 and Week 12
score on a scaleStage 1: AVP-786Stage 1: PlaceboStage 1 Placebo Non-responders; Stage 2: PlaceboStage 1 Placebo Non-responders; Stage 2: AVP-786Stage 1 Placebo Responders; Stage 2: PlaceboStage 1 Placebo Responders; Stage 2: AVP-786Stage 1 AVP-786; Stage 2: AVP-786
Week 63.6 ± 0.803.8 ± 0.77—————
Week 12——3.7 ± 0.753.5 ± 0.93———
Statistical analysis
  • Stage 1: AVP-786 vs Stage 1: Placebo vs Stage 1 Placebo Non-responders; Stage 2: Placebo vs Stage 1 Placebo Non-responders; Stage 2: AVP-786 · Mixed Models Analysis · p = 0.427 · Spcd weighted ols z-statistic: -0.79 · 95% CI -2.75 to 1.17
SecondaryMean Actual Clinical Global Impression of Change (CGI-C) Score at Week 6 and Week 12

The CGI is an assessment of the participant's global functioning prior to and after initiating a study medication and provides an overall clinician-determined summary measure that takes into account all available information, including knowledge of the participant's history, psychosocial circumstances, symptoms, behavior, and the impact of the symptoms on the participant's ability to function. It is based on a 7-point scale that requires the clinician to rate the change of the participant's condition at the time of assessment, relative to the clinician's past experience with the participant's condition at admission. Considering the total clinical experienced, a participant is assessed for change of mental illness as: 1 (very much improved); 2 (much improved); 3 (minimally improved); 4 (no change); 5 (minimally worse); 6 (much worse); or 7 (very much worse). Scores range from 1 to 7, with higher scores indicative of greater severity of illness.

Time frame:
Baseline, Week 6 (Stage 1), Week 12 (Stage 2)
Reported as:
Mean · score on a scale
Mean Actual Clinical Global Impression of Change (CGI-C) Score at Week 6 and Week 12
score on a scaleStage 1: AVP-786Stage 1: PlaceboStage 1 Placebo Non-responders; Stage 2: PlaceboStage 1 Placebo Non-responders; Stage 2: AVP-786Stage 1 Placebo Responders; Stage 2: PlaceboStage 1 Placebo Responders; Stage 2: AVP-786Stage 1 AVP-786; Stage 2: AVP-786
Week 63.4 ± 0.803.6 ± 0.69—————
Week 12——3.8 ± 0.903.5 ± 0.80———
Statistical analysis
  • Stage 1: AVP-786 vs Stage 1: Placebo vs Stage 1 Placebo Non-responders; Stage 2: Placebo vs Stage 1 Placebo Non-responders; Stage 2: AVP-786 · McNemar · p = 0.0566 · Spcd weighted ols z-statistic: -1.91 · 95% CI -3.87 to 0.05
SecondaryMean Actual Patient Global Impression of Change (PGI-C) Score at Week 6 at Week 12

The PGI-C is a 7-point, participant-rated scale used to assess treatment response as: 0=Not assessed; 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally 6=worse; or 7=very much worse. Week 6 and Week 12 scores are relative to Stage 1 Baseline.

Time frame:
Baseline, Week 6 (Stage 1), Week 12 (Stage 2)
Reported as:
Mean · score on a scale
Mean Actual Patient Global Impression of Change (PGI-C) Score at Week 6 at Week 12
score on a scaleStage 1: AVP-786Stage 1: PlaceboStage 1 Placebo Non-responders; Stage 2: PlaceboStage 1 Placebo Non-responders; Stage 2: AVP-786Stage 1 Placebo Responders; Stage 2: PlaceboStage 1 Placebo Responders; Stage 2: AVP-786Stage 1 AVP-786; Stage 2: AVP-786
Week 63.1 ± 0.943.2 ± 1.01—————
Week 12——3.3 ± 0.782.9 ± 1.11———
Statistical analysis
  • Stage 1: AVP-786 vs Stage 1: Placebo vs Stage 1 Placebo Non-responders; Stage 2: Placebo vs Stage 1 Placebo Non-responders; Stage 2: AVP-786 · ANCOVA · p = 0.1700 · Spcd weighted ols z-statistic: -1.37 · 95% CI -3.33 to 0.59
SecondaryChange From Baseline in the Calgary Depression Scale for Schizophrenia (CDSS) Total Score at Week 6 and Week 12

The CDSS is a 9-item scale derived from the Hamilton Depression Scale (Ham-D) that is designed to assess depression specifically in participants with schizophrenia. Unlike the Ham-D, the CDSS does not contain depressive symptoms that overlap with negative symptoms of schizophrenia, such as anhedonia and social withdrawal. Each item on the scale is scored as: 0 (absent); 1 (mild); 2 (moderate); or 3 (severe). The CDSS is obtained by adding each of the item scores. A score above 6 has an 82% specificity and 85% sensitivity for predicting the presence of a major depressive episode. The CDSS score ranges from 0 to 27, with higher scores indicative of severe symptoms of depression. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

Time frame:
Baseline and Week 6 (Stage 1); Baseline (Week 6) and Week 12 (Stage 2)
Reported as:
Mean · score on a scale
Change From Baseline in the Calgary Depression Scale for Schizophrenia (CDSS) Total Score at Week 6 and Week 12
score on a scaleStage 1: AVP-786Stage 1: PlaceboStage 1 Placebo Non-responders; Stage 2: PlaceboStage 1 Placebo Non-responders; Stage 2: AVP-786Stage 1 Placebo Responders; Stage 2: PlaceboStage 1 Placebo Responders; Stage 2: AVP-786Stage 1 AVP-786; Stage 2: AVP-786
Stage 1 Baseline1.1 ± 1.340.9 ± 1.31—————
Chane from Baseline at Week 6-0.2 ± 1.34-0.1 ± 1.02—————
Stage 2 Baseline——1.0 ± 1.560.8 ± 1.54———
Change from Baseline at Week 12——-0.4 ± 1.24-0.0 ± 1.66———
Statistical analysis
  • Stage 1: AVP-786 vs Stage 1: Placebo vs Stage 1 Placebo Non-responders; Stage 2: Placebo vs Stage 1 Placebo Non-responders; Stage 2: AVP-786 · Mixed Models Analysis · p = 0.595 · Spcd weighted ols z-statistic: 0.53 · 95% CI -1.43 to 2.49
SecondaryChange From Baseline in the Effort Expenditure for Reward Task (EEfRT) Score for Baseline Press Rate at Week 6 and Week 12

The EEfRT is a multi-trial computerized task in which participants are given the opportunity on each trial to choose between 2 tasks that differ in difficulty level and are associated with varying levels of monetary reward. The test measures drug effects on the willingness to expend effort in relation to the amount of reward or probability of reward. The ratio of hard task choices with moderate probability reward is used as an outcome measure for negative symptoms. EEfRT scores are analyzed for 8 variables. Variable 1 is the Baseline press rate and is defined as the value coded as average presses/second. Scores range from 0 to 9, with higher scores indicative of faster button pressing ability. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

Time frame:
Baseline and Week 6 (Stage 1); Baseline (Week 6) and Week 12 (Stage 2)
Reported as:
Mean · score on a scale
Change From Baseline in the Effort Expenditure for Reward Task (EEfRT) Score for Baseline Press Rate at Week 6 and Week 12
score on a scaleStage 1: AVP-786Stage 1: PlaceboStage 1 Placebo Non-responders; Stage 2: PlaceboStage 1 Placebo Non-responders; Stage 2: AVP-786Stage 1 Placebo Responders; Stage 2: PlaceboStage 1 Placebo Responders; Stage 2: AVP-786Stage 1 AVP-786; Stage 2: AVP-786
Stage 1 Baseline3.39 ± 1.1373.39 ± 1.112—————
Change from Baseline at Week 60.461 ± 0.8440.195 ± 1.181—————
Stage 2 Baseline——3.38 ± 1.2843.67 ± 0.904———
Change from Baseline at Week 12——-0.109 ± 0.9090.354 ± 1.076———
Statistical analysis
  • Stage 1: AVP-786 vs Stage 1: Placebo vs Stage 1 Placebo Non-responders; Stage 2: Placebo vs Stage 1 Placebo Non-responders; Stage 2: AVP-786 · ANCOVA · p = 0.022 · Spcd weighted ols z-statistic: 2.284 · 95% CI 0.324 to 4.244
SecondaryChange From Baseline in the EEfRT Score for Choice Reaction Time (RT) 1st 50 at Week 6 and Week 12

The EEfRT is a multi-trial computerized test that reliably measures drug effects on the willingness to expend effort in relation to the amount of reward or probability of reward. For each trial, participants are asked to choose between 2 tasks that differ in difficulty level and are associated with varying levels of monetary reward. EEfRT scores are analyzed for 8 variables. Variable 2 is the choice RT and is defined as the average RT measured in milliseconds for making a choice during the first 50 trials. Scores range from 0 to 10,000. The target range is greater than 500. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

Time frame:
Baseline and Week 6 (Stage 1); Baseline (Week 6) and Week 12 (Stage 2)
Reported as:
Mean · score on a scale
Change From Baseline in the EEfRT Score for Choice Reaction Time (RT) 1st 50 at Week 6 and Week 12
score on a scaleStage 1: AVP-786Stage 1: PlaceboStage 1 Placebo Non-responders; Stage 2: PlaceboStage 1 Placebo Non-responders; Stage 2: AVP-786Stage 1 Placebo Responders; Stage 2: PlaceboStage 1 Placebo Responders; Stage 2: AVP-786Stage 1 AVP-786; Stage 2: AVP-786
Stage 1 Baseline1339.5 ± 838.401659.4 ± 1063.02—————
Change from Baseline at Week 6-255.1 ± 551.65-346.6 ± 1108.63—————
Stage 2 Baseline——1309.4 ± 595.021283.5 ± 875.79———
Change from Baseline at Week 12——-288.8 ± 527.42-110.2 ± 812.66———
Statistical analysis
  • Stage 1: AVP-786 vs Stage 1: Placebo vs Stage 1 Placebo Non-responders; Stage 2: Placebo vs Stage 1 Placebo Non-responders; Stage 2: AVP-786 · ANCOVA · p = 0.862 · Spcd weighted ols z-statistic: -0.17 · 95% CI -2.13 to 1.79
SecondaryChange From Baseline in the EEfRT Score for Completed Tasks at Week 6 and Week 12

The EEfRT is a multi-trial computerized test that reliably measures drug effects on the willingness to expend effort in relation to the amount of reward or probability of reward. For each trial, participants are asked to choose between 2 tasks that differ in difficulty level and are associated with varying levels of monetary reward. EEfRT scores are analyzed for 8 variables. Variable 3 is the proportion of completed task (easy or hard) during the first 50 trials. Scores range from 0 to 1, with higher scores indicative of better task compliance. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

Time frame:
Baseline and Week 6 (Stage 1); Baseline (Week 6) and Week 12 (Stage 2)
Reported as:
Mean · score on a scale
Change From Baseline in the EEfRT Score for Completed Tasks at Week 6 and Week 12
score on a scaleStage 1: AVP-786Stage 1: PlaceboStage 1 Placebo Non-responders; Stage 2: PlaceboStage 1 Placebo Non-responders; Stage 2: AVP-786Stage 1 Placebo Responders; Stage 2: PlaceboStage 1 Placebo Responders; Stage 2: AVP-786Stage 1 AVP-786; Stage 2: AVP-786
Stage 1 Baseline0.790 ± 0.2850.749 ± 0.294—————
Change from Baseline at Week 6-0.032 ± 0.1960.001 ± 0.209—————
Stage 2 Baseline——0.703 ± 0.3290.779 ± 0.254———
Change from Baseline at Week 12——0.049 ± 0.223-0.022 ± 0.173———
Statistical analysis
  • Stage 1: AVP-786 vs Stage 1: Placebo vs Stage 1 Placebo Non-responders; Stage 2: Placebo vs Stage 1 Placebo Non-responders; Stage 2: AVP-786 · ANCOVA · p = 0.251 · Spcd weighted ols z-statistic: -1.149 · 95% CI -3.109 to 0.811
SecondaryChange From Baseline in the EEfRT Score for 12% Probability-Proportion High Effort Opts at Week 6 and Week 12

The EEfRT is a multi-trial computerized test that reliably measures drug effects on the willingness to expend effort in relation to the amount of reward or probability of reward. For each trial, participants are asked to choose between 2 tasks that differ in difficulty level and are associated with varying levels of monetary reward. EEfRT scores are analyzed for 8 variables. Variable 4 is the proportion of hard task choices made for the low (12%) probability condition during the first 50 trials of the task. Scores range from 0 to 1, with higher scores indicative of greater effort expenditure. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

Time frame:
Baseline and Week 6 (Stage 1); Baseline (Week 6) and Week 12 (Stage 2)
Reported as:
Mean · score on a scale
Change From Baseline in the EEfRT Score for 12% Probability-Proportion High Effort Opts at Week 6 and Week 12
score on a scaleStage 1: AVP-786Stage 1: PlaceboStage 1 Placebo Non-responders; Stage 2: PlaceboStage 1 Placebo Non-responders; Stage 2: AVP-786Stage 1 Placebo Responders; Stage 2: PlaceboStage 1 Placebo Responders; Stage 2: AVP-786Stage 1 AVP-786; Stage 2: AVP-786
Stage 1 Baseline0.080 ± 0.0710.0755 ± 0.079—————
Change from Baseline at Week 6-0.021 ± 0.064-0.004 ± 0.082—————
Stage 2 Baseline——0.040 ± 0.0490.071 ± 0.063———
Change from Baseline at Week 12——0.000 ± 0.045-0.027 ± 0.051———
Statistical analysis
  • Stage 1: AVP-786 vs Stage 1: Placebo vs Stage 1 Placebo Non-responders; Stage 2: Placebo vs Stage 1 Placebo Non-responders; Stage 2: AVP-786 · ANCOVA · p = 0.246 · Spcd weighted ols z-statistic: -1.159 · 95% CI -3.119 to 0.801
SecondaryChange From Baseline in the EEfRT Score for 50% Probability-Proportion High Effort Opts 1st 50 at Week 6 and Week 12

The EEfRT is a multi-trial computerized test that reliably measures drug effects on the willingness to expend effort in relation to the amount of reward or probability of reward. For each trial, participants are asked to choose between 2 tasks that differ in difficulty level and are associated with varying levels of monetary reward. EEfRT scores are analyzed for 8 variables. Variable 5 is the proportion of hard task choices made for the medium (50%) probability condition during the first 50 trials of the task. Scores range from 0 to 1, with higher scores indicative of greater effort expenditure. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

Time frame:
Baseline and Week 6 (Stage 1); Baseline (Week 6) and Week 12 (Stage 2)
Reported as:
Mean · score on a scale
Change From Baseline in the EEfRT Score for 50% Probability-Proportion High Effort Opts 1st 50 at Week 6 and Week 12
score on a scaleStage 1: AVP-786Stage 1: PlaceboStage 1 Placebo Non-responders; Stage 2: PlaceboStage 1 Placebo Non-responders; Stage 2: AVP-786Stage 1 Placebo Responders; Stage 2: PlaceboStage 1 Placebo Responders; Stage 2: AVP-786Stage 1 AVP-786; Stage 2: AVP-786
Stage 1 Baseline0.088 ± 0.0700.078 ± 0.081—————
Change from Baseline at Week 6-0.026 ± 0.055-0.012 ± 0.102—————
Stage 2 Baseline——0.060 ± 0.0570.062 ± 0.078———
Change from Baseline at Week 12——-0.016 ± 0.068-0.005 ± 0.083———
Statistical analysis
  • Stage 1: AVP-786 vs Stage 1: Placebo vs Stage 1 Placebo Non-responders; Stage 2: Placebo vs Stage 1 Placebo Non-responders; Stage 2: AVP-786 · ANCOVA · p = 0.818 · Spcd weighted ols z-statistic: 0.231 · 95% CI -1.729 to 2.191
SecondaryChange From Baseline in the EEfRT Score for 88% Probability-Proportion High Effort Opts 1st 50 at Week 6 and Week 12

The EEfRT is a multi-trial computerized test that reliably measures drug effects on the willingness to expend effort in relation to the amount of reward or probability of reward. For each trial, participants are asked to choose between 2 tasks that differ in difficulty level and are associated with varying levels of monetary reward. EEfRT scores are analyzed for 8 variables. Variable 6 is the proportion of hard task choices made for the hard (88%) probability condition during the first 50 trials of the task. Scores range from 0 to 1, with higher scores indicative of greater effort expenditure. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

Time frame:
Baseline and Week 6 (Stage 1); Baseline (Week 6) and Week 12 (Stage 2)
Reported as:
Mean · score on a scale
Change From Baseline in the EEfRT Score for 88% Probability-Proportion High Effort Opts 1st 50 at Week 6 and Week 12
score on a scaleStage 1: AVP-786Stage 1: PlaceboStage 1 Placebo Non-responders; Stage 2: PlaceboStage 1 Placebo Non-responders; Stage 2: AVP-786Stage 1 Placebo Responders; Stage 2: PlaceboStage 1 Placebo Responders; Stage 2: AVP-786Stage 1 AVP-786; Stage 2: AVP-786
Stage 1 Baseline0.082 ± 0.0630.081 ± 0.086—————
Change from Baseline at Week 6-0.021 ± 0.072-0.006 ± 0.097—————
Stage 2 Baseline——0.052 ± 0.0650.078 ± 0.074———
Change from Baseline at Week 12——-0.015 ± 0.047-0.015 ± 0.070———
Statistical analysis
  • Stage 1: AVP-786 vs Stage 1: Placebo vs Stage 1 Placebo Non-responders; Stage 2: Placebo vs Stage 1 Placebo Non-responders; Stage 2: AVP-786 · ANCOVA · p = 0.968 · Spcd weighted ols z-statistic: -0.040 · 95% CI -2.00 to 1.92
SecondaryChange From Baseline in the EEfRT Score for All-Proportion High Effort Opts 1st 50 at Week 6 and Week 12

The EEfRT is a multi-trial computerized test that reliably measures drug effects on the willingness to expend effort in relation to the amount of reward or probability of reward. For each trial, participants are asked to choose between 2 tasks that differ in difficulty level and are associated with varying levels of monetary reward. EEfRT scores are analyzed for 8 variables. Variable 7 is the overall proportion of hard task choices made for the first 50 trials of the task. Scores range from 0 to 1, with higher scores indicative of greater effort expenditure. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

Time frame:
Baseline and Week 6 (Stage 1); Baseline (Week 6) and Week 12 (Stage 2)
Reported as:
Mean · score on a scale
Change From Baseline in the EEfRT Score for All-Proportion High Effort Opts 1st 50 at Week 6 and Week 12
score on a scaleStage 1: AVP-786Stage 1: PlaceboStage 1 Placebo Non-responders; Stage 2: PlaceboStage 1 Placebo Non-responders; Stage 2: AVP-786Stage 1 Placebo Responders; Stage 2: PlaceboStage 1 Placebo Responders; Stage 2: AVP-786Stage 1 AVP-786; Stage 2: AVP-786
Stage 1 Baseline0.251 ± 0.1850.234 ± 0.234—————
Change from Baseline at Week 6-0.068 ± 0.167-0.022 ± 0.261—————
Stage 2 Baseline——0.152 ± 0.1610.210 ± 0.199———
Change from Baseline at Week 12——-0.032 ± 0.144-0.047 ± 0.176———
Statistical analysis
  • Stage 1: AVP-786 vs Stage 1: Placebo vs Stage 1 Placebo Non-responders; Stage 2: Placebo vs Stage 1 Placebo Non-responders; Stage 2: AVP-786 · ANCOVA · p = 0.760 · Spcd weighted ols z-statistic: -0.306 · 95% CI -2.266 to 1.654
SecondaryChange From Baseline in the EEfRT Score for Difference - Proportion High Effort Opts 1st 50 at Week 6 and Week 12

The EEfRT is a multi-trial computerized test that reliably measures drug effects on the willingness to expend effort in relation to the amount of reward or probability of reward. For each trial, participants are asked to choose between 2 tasks that differ in difficulty level and are associated with varying levels of monetary reward. EEfRT scores are analyzed for 8 variables. Variable 8 is the difference between the proportion of hard task choices made for the high probability condition during the first 50 trials of the task. Scores range from -1 to 1, with higher scores indicative of greater sensitivity to probability information. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

Time frame:
Baseline and Week 6 (Stage 1); Baseline (Week 6) and Week 12 (Stage 2)
Reported as:
Mean · score on a scale
Change From Baseline in the EEfRT Score for Difference - Proportion High Effort Opts 1st 50 at Week 6 and Week 12
score on a scaleStage 1: AVP-786Stage 1: PlaceboStage 1 Placebo Non-responders; Stage 2: PlaceboStage 1 Placebo Non-responders; Stage 2: AVP-786Stage 1 Placebo Responders; Stage 2: PlaceboStage 1 Placebo Responders; Stage 2: AVP-786Stage 1 AVP-786; Stage 2: AVP-786
Stage 1 Baseline0.002 ± 0.0410.006 ± 0.037—————
Change from Baseline at Week 6-0.001 ± 0.054-0.002 ± 0.050—————
Stage 2 Baseline——0.012 ± 0.0320.006 ± 0.034———
Change from Baseline at Week 12——-0.015 ± 0.0370.012 ± 0.039———
Statistical analysis
  • Stage 1: AVP-786 vs Stage 1: Placebo vs Stage 1 Placebo Non-responders; Stage 2: Placebo vs Stage 1 Placebo Non-responders; Stage 2: AVP-786 · ANCOVA · p = 0.214 · Spcd weighted ols z-statistic: 1.243 · 95% CI -0.717 to 3.203
SecondaryNumber of Participants With a Reduction of 20% or Greater in the PANSS Total Score at Week 6 and Week 12

Treatment effect was evaluated by analyzing the proportion of participants with a 20% reduction from Baseline in the PANSS total score with SPCD analysis.

Time frame:
Baseline and Week 6 (Stage 1); Baseline (Week 6) and Week 12 (Stage 2)
Reported as:
Count of participants · Participants
Number of Participants With a Reduction of 20% or Greater in the PANSS Total Score at Week 6 and Week 12
ParticipantsStage 1: AVP-786Stage 1: PlaceboStage 1 Placebo Non-responders; Stage 2: PlaceboStage 1 Placebo Non-responders; Stage 2: AVP-786Stage 1 Placebo Responders; Stage 2: PlaceboStage 1 Placebo Responders; Stage 2: AVP-786Stage 1 AVP-786; Stage 2: AVP-786
Week 6; Response = Yes53—————
Week 6; Response = No4277—————
Week 12; Response = Yes——13———
Week 12; Response = No——2930———
Statistical analysis
  • Stage 1: AVP-786 vs Stage 1: Placebo vs Stage 1 Placebo Non-responders; Stage 2: Placebo vs Stage 1 Placebo Non-responders; Stage 2: AVP-786 · SPCD 1 degree of freedom score test · p = 0.071
SecondaryChange From Baseline in the 4-Item NSA (NSA-4) Total Score at Week 6 and Week 12

The NSA-4 is comprised of the 4 NSA-16 items as follows: 1) restricted speech quantity, 2) emotion: reduced range, 3) reduced social drive, and 4) reduced interests, as well as an overall global rating of negative symptoms. The NSA-16 is a measure of the presence, severity, and range of negative symptoms associated with schizophrenia. It has a high interrater and test-retest reliability across languages and cultures. The possible NSA-4 total score ranges from 4 to 24, with higher scores indicating greater clinical severity of symptoms. Change was Baseline was calculated as the post-Baseline value minus the Baseline value.

Time frame:
Baseline and Week 6 (Stage 1); Baseline (Week 6) and Week 12 (Stage 2)
Reported as:
Mean · score on a scale
Change From Baseline in the 4-Item NSA (NSA-4) Total Score at Week 6 and Week 12
score on a scaleStage 1: AVP-786Stage 1: PlaceboStage 1 Placebo Non-responders; Stage 2: PlaceboStage 1 Placebo Non-responders; Stage 2: AVP-786Stage 1 Placebo Responders; Stage 2: PlaceboStage 1 Placebo Responders; Stage 2: AVP-786Stage 1 AVP-786; Stage 2: AVP-786
Stage 1 Baseline17.4 ± 2.4417.3 ± 2.36—————
Change from Baseline at Week 6-1.0 ± 2.10-1.0 ± 1.92—————
Stage 2 Baseline——16.5 ± 2.6416.4 ± 2.84———
Change from Baseline at Week 12——-0.5 ± 2.01-0.5 ± 1.93———
Statistical analysis
  • Stage 1: AVP-786 vs Stage 1: Placebo vs Stage 1 Placebo Non-responders; Stage 2: Placebo vs Stage 1 Placebo Non-responders; Stage 2: AVP-786 · Mixed Models Analysis · p = -0.06 · Spcd weighted ols z-statistic: 0.951 · 95% CI -1.009 to 2.911

Adverse events

Collected over All adverse events (AEs) were collected for approximately 90 days.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
All Placebo0/96 (0%)2/96 (2.1%)39/96 (40.6%)
All AVP-7860/88 (0%)0/88 (0%)30/88 (34.1%)
Most frequent serious events
Most frequent serious events
EventAll PlaceboAll AVP-786
Urinary tract infectionInfections and infestations1/960/88
SchizophreniaPsychiatric disorders1/960/88
Most frequent other events
Showing 10 of 74
Most frequent other events
EventAll PlaceboAll AVP-786
HeadacheNervous system disorders5/962/88
Dry mouthGastrointestinal disorders1/964/88
NasopharyngitisInfections and infestations4/963/88
DizzinessNervous system disorders3/963/88
DiarrhoeaGastrointestinal disorders3/962/88
SomnolenceNervous system disorders3/961/88
Upper respiratory tract infectionInfections and infestations0/962/88
Blood creatine phosphokinase increasedInvestigations0/962/88
Vision blurredEye disorders0/962/88
SedationNervous system disorders2/960/88

Baseline characteristics

Baseline data are reported for members of the Safety Population, comprised of all participants who received at least one dose of study medication.

Age, Continuous
Age, Continuous(Years)PlaceboAVP-786Total
Mean44.9 ± 10.8346.5 ± 12.0445.4 ± 11.23
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboAVP-786Total
Female271845
Male693099
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboAVP-786Total
Hispanic or Latino12416
Not Hispanic or Latino8444128
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboAVP-786Total
American Indian or Alaska Native000
Asian448
Native Hawaiian or Other Pacific Islander000
Black or African American532578
White361854
More than one race000
Unknown or Not Reported314
08

Study locations

17 sites
  • Cerritos, California, United States
  • Garden Grove, California, United States
  • National City, California, United States
  • Oakland, California, United States
  • San Diego, California, United States
  • Washington D.C., District of Columbia, United States
  • Orlando, Florida, United States
  • Atlanta, Georgia, United States
  • Augusta, Georgia, United States
  • Chicago, Illinois, United States
  • Boston, Massachusetts, United States
  • Worcester, Massachusetts, United States
  • Grand Rapids, Michigan, United States
  • Marlton, New Jersey, United States
  • Jamaica, New York, United States
  • New York, New York, United States
  • Rochester, New York, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2015 to primary completion in Jul 2017, 22 months.

Results were first posted in Sep 2020, 3 years 1 month after primary completion. A results delay was requested in Jul 2018.

Of 57 industry-sponsored phase 2 interventional studies under Schizophrenia, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 32. This study's 22 months is close to that.

Counting every sponsor, half of 101 studies reached it within 25 months; a quarter within 15 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 18, 2015
First posted
Jun 23, 2015
StartActual
Sep 1, 2015
Primary completionActual
Jul 21, 2017
CompletionActual
Jul 21, 2017
Results delay requested
Jul 30, 2018
Results first posted
Sep 16, 2020
Last update
May 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02477670
Responsible party
Sponsor
First posted
Jun 23, 2015
Start date
Sep 1, 2015
Primary completion
Jul 21, 2017
Completion
Jul 21, 2017
Results posted
Sep 16, 2020
Last update
May 13, 2026

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Deudextromethorphan · Quinidine

Start the discussion